Open-market purchases of BlossomHill Therapeutics, Inc. (BLSM) stock by its own executives, directors and 10% owners — every Form 4 buy of $250K or more that SPX Lens's daily insider scan has recorded, newest first.
| Scan | Insider | Value | Type | |||
|---|---|---|---|---|---|---|
| Aug 11, 2026 | Bihua ChenDirector | $5.00M | Added | |||
| IPO-day purchase at offering price ($16.00). Bihua Chen (Cormorant Asset Management) previously held pre-IPO preferred stock (Series A & B); the 312,500 P-coded shares represent fresh capital added at the listing. BLSM raised $150M upsized IPO on Nasdaq for EGFR-mutant lung cancer inhibitor BH-30643. Now $15.99 (−0.1% from buy). | ||||||
Source: insiders' SEC Form 4 filings — open-market purchases (transaction code P) of $250K or more filed in the previous day. Insiders must file within two business days of a trade, so a purchase can be a day or two older than its filing. Average price = value ÷ shares. Insiders buy for many reasons and a purchase is no guarantee the shares will rise. The summaries are written by AI as a research aid — not financial advice or a recommendation to buy or sell any security, and they can be wrong.
SPX Lens Insider Buying reads the SEC Form 4 filings insiders file after trading their own company's stock and lists every open-market purchase of $250K or more — who bought, their role, how much and at what average price. Insiders sell for many reasons, but they usually buy for one: they think the shares are worth more. It is free, and a new scan is posted every trading day. How to read insider buying →
See where SPX is heading next. The SPX Lens chart shows key levels, live signals and an AI forecast for the next bars — free to try.
Open the live chartOpen in the Stocks tab© SPX Lens · About · Terms · Privacy — for educational purposes only, not financial advice.